YGYing Guo

Ying Guo

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Ying Guo has a total of 59 co-authors. Here are the top co-authors by number of shared publications:

  • Mengyu Shi

    The First Clinical College, Shandong University of Traditional Chinese Medicine, Jinan, People’s Republic of China

    4 shared publications
  • Wenlong Qi

    The First Clinical College, Shandong University of Traditional Chinese Medicine, Jinan, People’s Republic of China

    4 shared publications
  • Xinwei Sun

    The First Clinical College, Shandong University of Traditional Chinese Medicine, Jinan, People’s Republic of China

    4 shared publications
  • Xinxin Yang

    The First Clinical College, Shandong University of Traditional Chinese Medicine, Jinan, People’s Republic of China

    4 shared publications
  • Zhicheng Jia

    Department of Gynecology, Guang’anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, People’s Republic of China

    4 shared publications
  • Peixuan Wang

    The First Clinical College, Shandong University of Traditional Chinese Medicine, Jinan, China

    3 shared publications

Latest Publications

  • Open Access

    Chemotherapy-Associated Ovarian Damage: Pathological Mechanisms and Current Interventions

    by Wenlong Qi, Zhicheng Jia, Mengyu Shi, Xinxin Yang, Xinwei Sun, Haiying Zhou, Ying Guo

    Chemotherapy drugs such as cyclophosphamide (CTX), doxorubicin (DOX), and cisplatin (CIS) are widely used in the treatment of malignant tumors, including head and neck cancers, leukemia, ovarian cancer, and breast cancer. However, these drugs are frequently associated with severe side effects, particularly ovarian toxicity, which significantly compromises fertility and quality of life in female patients. Current research has revealed that chemotherapy associated ovarian damage(CAOD) involves a range of pathological and molecular mechanisms, including extracellular matrix(ECM) deposition, stromal fibrosis, ovarian vascular injury, DNA damage, redox imbalance, immune microenvironment dysregulation, and excessive activation of primordial follicles(PMFs). From a clinical perspective, embryo and oocyte cryopreservation, as well as ovarian tissue cryopreservation in appropriate patients, represent established fertility-preservation approaches, whereas ovarian-protective interventions such as GnRH agonists (GnRHa) remain subject to ongoing clinical evaluation. In contrast, stem cell therapy, antiapoptotic agents, antioxidants, and strategies targeting excessive follicle activation are predominantly supported by preclinical evidence and have not yet been established as routine clinical treatments. This article provides a narrative review of the major pathological features and molecular mechanisms of chemotherapy-induced ovarian damage, evaluates the limitations of existing prevention and treatment strategies, and aims to advance academic discourse in the field of CAOD prevention and treatment, while offering insights for future research.

  • Open Access

    Molecular characteristics of follicular fluid in advanced maternal age women with different ovarian reserves: a multi-omics study

    by Wenlong Qi, Zhicheng Jia, Mengyu Shi, Xinxin Yang, Xinwei Sun, Yongqian Li, Peixuan Wang, Ying Guo

    Age-related diminished ovarian reserve (DOR) exhibits marked significant individual variation. Some women of advanced age with normal ovarian reserve (NOR)


  • Open Access

    Age-related mitochondrial energy metabolism reprogramming occurs in granulosa cells during ovarian aging

    by Mengyu Shi, Zhicheng Jia, Xinxin Yang, Wenlong Qi, Xinwei Sun, Yongqian Li, Peixuan Wang, Ying Guo

    Objective: Ovarian aging is an inevitable age-associated biological phenomenon.Enhancing clinical pregnancy outcomes in women with advanced maternal age (AMA) has emerged as a critical research priority in reproductive medicine. The current study seeks to unravel the mechanism governing mitochondrial energy metabolism reprogramming in granulosa cells (GCs) during age-associated ovarian aging. Methods: We conducted an age-stratified prospective observational study involving GC samples from 10 young infertile women (young group: 21–34 years) and 10 infertile women with AMA (AMA group: 35–42 years), all undergoing in vitro fertilization-embryo transfer (IVF-ET). Participants were recruited from November 2023 to November 2024. Additionally, an in vitro oxidative stress-induced senescence model was established using hydrogen peroxide (H 2 O 2 )-treated human ovarian granulosa-like tumor cell line (KGN cells) to further investigate metabolic disturbances and mitochondrial reactive oxygen species (mtROS) levels in senescent GCs. Results: High-resolution targeted metabolomics revealed 25 statistically significant metabolite alterations in ovarian GCs, indicating profound dysregulation of core energy metabolism pathways—particularly oxidative phosphorylation (OXPHOS), glycolysis, and the tricarboxylic acid (TCA) cycle. Compared to the young group, the AMA group exhibited upregulated glycolytic metabolites alongside downregulated OXPHOS and TCA cycle intermediates. These findings were further validated in an H 2 O 2 -induced KGN cells senescence model, where treated cells demonstrated: (1) increased senescence-associated β-galactosidase (SA-β-gal) activity, (2) elevated extracellular acidification rate (ECAR) and lactate (Lac) production, (3) reduced oxygen consumption rate (OCR), (4) depleted glucose and pyruvate(Pyr) pools, and (5) heightened mtROS generation relative to control group. Conclusions: Collectively, our research demonstrates that GCs undergo mitochondrial energy metabolism reprogramming, characterized by a metabolic shift from OXPHOS to glycolysis, during ovarian aging. These observations suggest that age-associated glycometabolic perturbations may represent a novel therapeutic target for infertility in women with AMA.


  • Open Access

    Non-hormone replacement therapy to overcome premature ovarian insufficiency: advances in natural products and stem cells targeting autophagy

    by Xinxin Yang, Zhicheng Jia, Mengyu Shi, Yongqian Li, Guangheng Zhang, Peixuan Wang, Xinwei Sun, Wenlong Qi, Ying Guo

    Premature ovarian insufficiency (POI) is the most common cause of female infertility. With the increase in people’s bad life habits, the causative factors of POI have increased, and its incidence has shown a rising trend year by year. At present, the commonly used clinical treatment for POI is hormonal replacement therapy (HRT), but it is not universally applicable and is prone to cause subsequent complications, posing certain health risks to patients with POI. Therefore, exploring greener, safer, and more efficacious non-hormonal treatments can help to address the clinical challenges of POI-induced infertility better. Studies have shown that autophagy plays a key role in the development and degeneration of oocytes from their origin to the follicle and that any alteration in autophagy affects the ovarian reserve in the follicle. Moreover, certain natural products and human stem cells from different sources can treat POI by modulating the autophagic pathway and have shown good efficacy. Therefore, our study aimed to review and analyze the previous research-based literature on natural product and stem cell therapy based on the autophagy mechanism of POI, and provide new insights and references for related scholars to continue to explore the autophagy mechanism of POI and non-hormone-targeted therapeutic strategies in depth.


  • Open Access

    ErZhiTianGui Decoction alleviates age-related ovarian aging by regulating mitochondrial homeostasis and inhibiting ferroptosis

    by Jia Zhicheng, Li Yongqian, Wang Peixuan, Yang Kai, Shi Mengyu, Chen Wen, Liang Qihui, Guo Ying

    Aim: This study was designed to investigate the pharmacological effects and mechanisms of ErZhiTianGui Decoction (EZTG) for age-related ovarian aging in mice. Methods: This study used naturally aging mice as a model, and EZTG was used for intragastric administration. Ovarian pathological changes, as well as follicular reserve were assessed by hematoxylin and eosin staining, and serum hormone levels (anti-mullerian hormone, follicle-stimulating hormone), mitochondrial reactive oxygen species (ROS) and mitochondrial DNA (mtDNA) damage marker 8-hydroxy-2′-deoxyguanosine(8-OHdG), and lipid peroxidation markers glutathione(GSH) and malondialdehyde(MDA) were determined by enzyme-linked immunosorbent assay. Mitochondrial membrane potential (MMP) levels in ovaries were determined using flow cytometry. The levels of PINK1 and Parkin were observed using immunofluorescence staining. Mitochondrial-derived vesicles (MDVs) and mitochondrial morphology were observed using electron microscopy. Prussian blue staining was used to observe iron ion aggregation in ovarian tissue. The Iron assay kits detected total iron levels. Western blot was used to detect the expression of proteins related to mitochondrial and ferroptosis related genes. Results: After EZTG treatment, aged mice showed increased ovarian reserve, improved serum hormone levels, increased MMP, GSH levels, and decreased mitochondrial ROS, 8-OHdG, and MDA levels. Immunofluorescence staining showed decreased levels of PINK1 and Parkin, and the same trend was observed for the Western blot. Meanwhile, electron microscopy showed that EZTG improved the mitochondrial morphology in the ovaries of aged mice. EZTG also decreased the total iron and protein levels of Acyl-CoA synthetase long-chain family4 (ACSL4) and increased the protein level of glutathione peroxidase 4 (GPX4) in the ovaries of aged mice. Conclusions: EZTG can maintain PINK1/Parkin-mediated mitochondrial homeostasis, reduce the lipid peroxidation caused by the accumulation of ROS, and inhibit the occurrence of ferroptosis and delaying ovarian aging. These findings suggest that EZTG may be a promising drug for treating age-related ovarian aging in females.


  • Open Access

    Transcriptomic profiling of human granulosa cells between women with advanced maternal age with different ovarian reserve

    by Zhi-Cheng Jia, Yong-Qian Li, Bo-Wen Zhou, Qing-Chang Xia, Pei-Xuan Wang, Xiao-Xuan Wang, Zhen-Gao Sun, Ying Guo

    Background: Age-related diminished ovarian reserve (DOR) is not absolute. Some advanced maternal age (AMA) still have normal ovarian reserve (NOR) and often show better pregnancy outcomes. Exploring the transcriptomic profile of granulosa cells (GCs) in AMA could lead to new ideas for mitigating age-related diminished ovarian reserve. Aim: This study aimed to analyze the transcriptomic profile of GCs in AMA with different ovarian reserve. Results: In total, 6273 statistically significant differential expression genes (DEGs) (|log2fc|> 1, q < 0.05) were screened from the two groups, among which 3436 genes were upregulated, and 2837 genes were downregulated in the DOR group. Through Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis, the potential functions of dysregulated genes in AMA with DOR or NOR were predicted. The GO enrichment analysis revealed that the DEGs were mainly enriched in obsolete oxidation–reduction process, mitochondrion, metal ion binding, ATP binding, etc. The KEGG pathway enrichment analysis revealed that the above-mentioned DEGs were mainly enriched in ferroptosis, regulation of actin cytoskeleton, oxidative phosphorylation, etc. Meanwhile, verification of the mRNA expression levels of DEGs revealed the possible involvement of “ferroptosis” in age-related diminished ovarian reserve. Conclusions: From a new clinical perspective, we presented the first data showing the transcriptomic profile in GCs between AMA with different ovarian reserve. At the same time, we identified the role of ferroptosis in the GCs of AMA, providing a new biological basis for studying ovarian aging and improving pregnancy outcomes of AMA.


  • Open Access

    Comparison of two different starting dose of rhFSH in GnRH antagonist protocol for patients with normal ovarian reserve

    by Zhi-Cheng Jia, Yong-Qian Li, Ran Li, Sen Hou, Qing-Chang Xia, Kai Yang, Pei-Xuan Wang, Shu-Miao Li, Zhen-Gao Sun, Ying Guo

    Objective: To evaluate different starting doses of recombinant human follicle-stimulating hormone (rhFSH) on pregnancy outcomes for patients with normal ovarian reserve during gonadotropin- releasing hormone antagonist (GnRH-ant) protocol-controlled ovarian stimulation of in vitro fertilization (IVF) cycles.Methods: In this retrospective study, a total of 1138 patients undergoing IVF cycles following the GnRH-ant protocol were enrolled. Patients were divided into two groups according to the starting dose of rhFSH. 617 patients received a starting dose of rhFSH of 150 IU, and 521 patients received a starting dose of rhFSH of 225 IU. We compared demographic characteristics, ovarian stimulation and embryological characteristics, and pregnancy and birth outcomes between the two groups. Multivariate logistic regression analysis was performed to examine the possible effects of the known potential confounding factors on pregnancy outcomes.Results: The number of oocytes retrieved in the 150 IU rhFSH group was significantly lower than those in the 225 IU rhFSH group. There was no significant difference between the two groups referring to embryological characteristics. The proportion of fresh embryo transfer in the 150 IU rhFSH group was significantly higher than that in the 225 IU rhFSH group (48.30% vs. 40.90%), and there was no difference in the risk of ovarian hyperstimulation syndrome and pregnancy outcomes between the two groups.Conclusions: In conclusion, the starting dose of rhFSH of 150 IU for ovarian stimulation has a similar pregnancy outcome as starting dose of rhFSH of 225 IU in GnRH-ant protocol for patients with normal ovarian reserve. Considering the potential cost-effectiveness and shorter time to live birth, the starting dose of rhFSH of 150 IU may be more suitable than 225 IU.


  • Open Access

    The predictive performance of the lactate clearance rate combined with the APACHE II score in the prediction of sepsis-associated acute kidney injury in 7 days

    by Yezhou Shen, Jiaoyang Yu, Fei Zhou, Juzhen Yan, Jing Yang, Ying Guo, Leqing Lin

    Background: The purpose of this study was to evaluate the accuracy of the lactate clearance rate (LCR) combined with the Acute Physiology and Chronic Health Evaluation II (APACHE II) score in the prediction of sepsis-associated acute kidney injury (SAKI). Methods: Sepsis patients were divided into the SAKI group and non-SAKI group. Arterial blood lactate was collected at 0 h (before treatment), 2 h, 4 h, 6 h, and 8 h (after treatment), and the LCR was calculated. The physiological parameters and laboratory test results were used to calculate the APACHE II score and the Sequential Organ Failure Assessment (SOFA) score. The receiver operating characteristic (ROC) curves of LCR, APACHE II score and SOFA score for predicting patients with SAKI were drawn. Two single indicators with high areas under the curves (AUCs) were selected to calculate the joint probability through regression analysis, and the prediction efficiency corresponding to each curve was analyzed. Results: There were significant differences in LCR between different groups and time periods (Fgroup=17.44, Pgroup ≤0.0001, Ftime =11.71, Ptime =0.0014). After 8 h of treatment, there was a significant difference in the overall compliance rate between the 2 groups (PConclusions: The 0–8 h LCR combined with APACHE II score can improve the early predictive value of SAKI, reduce the risk of AKI in patients with sepsis/septic shock, and reduce the social and family burden, which is worthy of clinical application.


  • A phase III study of comparing FOLFOX+/-bevacizumab with FOLFOX+/-bevacizumab+ high-dose intravenous vitamin C as first-line therapy in patients with advanced colorectal cancer.

    by Feng Wang, Jian Xiao, Yan-Qiao Zhang, Xianglin Yuan, Weijia Fang, Wei Wang, Xiaohua Hu, Zhixiang Zhuang, Fuxiang Zhou, Jieer Ying, et al.

    TPS4115 Background: Previous studies showed that high dose vitamin C especially when administered intravenously might have anti-cancer effect. A recent preclinical study found that human colorectal cancer cells harboring KRAS or BRAF mutations are selectively killed by high dose vitamin C. Our phase I dose-escalation and expansion study has shown that high dose (up to 1.5g/kg) intravenous vitamin C with FOLFOX or FOLFIRI is well tolerated in patients with colorectal or gastric cancer. This trial is a randomized, multicenter, phase Ⅲ study of high dose vitamin C infusion combined with FOLFOX +/- bevacizumab versus FOLFOX +/- bevacizumab as first-line therapy in patients with advanced colorectal cancer. Methods: This study has enrolled patients with histologically confirmed metastatic adenocarcinoma of colorectum, normal G6PD status and no prior treatment for metastatic disease. 432 patients are randomized 1:1 into one of two groups. Patients in the control group are treated with mFOLFOX6 (oxaliplatin 85 mg/m² d1 concurrent with leucovorin 400 mg/m², followed by bolus 5FU 400 mg/m² d1, followed by infusional 5FU 2400 mg/m² over 46 hours) with or without bevacizumab (5mg/kg, d1) every 2 weeks. Patients in the experimental group are treated with vitamin C intravenously (1.5g/kg/day, d1-3) in combination with mFOLFOX6 with or without bevacizumab every 2 weeks. Randomization is stratified by the location of primary site (left-sided or right-sided) and treatment with bevacizumab (with or without). The primary endpoint is progression free survival (assessed by investigator per RECIST v1.1). Secondary endpoints are overall survival, response rate, assessment of treatment-related adverse events, progression free survival and overall survival in RAS or BRAF mutant patients. Genome, microbiome and metabolome are also assessed. Clinical trial information: NCT02969681.


  • Human Follicular Fluid Metabolomics Study of Follicular Development and Oocyte Quality

    by Zhengao Sun, Haicui Wu, Fang Lian, Xingxing Zhang, Conghui Pang, Ying Guo, Jingyan Song, Aijuan Wang, Lei Shi, Letian Han